Literature DB >> 8115426

Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment.

F Rodríguez de Fonseca1, M A Gorriti, J J Fernández-Ruiz, T Palomo, J A Ramos.   

Abstract

Specific cannabinoid receptors have been recently described in extrapyramidal and limbic areas and presumably might mediate the effects of marijuana exposure on behavioral processes related to those areas. In this work, we examined whether cannabinoid receptors exhibit downregulation as a consequence of the chronic exposure to delta 9-tetrahydrocannabinol (THC), which might explain certain tolerance phenomena observed in relation to motor and limbic effects of marijuana. To this end, we first characterized the binding of cannabinoid receptors, by using [3H]CP-55,940 binding assays, in the striatum, limbic forebrain, and ventral mesencephalon of male rats, and, second, we measured the density and affinity of those receptors in these brain areas after 7 days of a daily treatment with THC. Development of a tolerance phenomenon was behaviorally tested by using an open-field technique. Results were as follows. The three areas studies presented specific and saturable binding for the cannabinoid ligand, as revealed by their corresponding association and dissociation curves, displacement by THC, saturation curves, and Scatchard plots. A chronic treatment with THC produced the expected tolerance phenomenon: The decrease caused by an acute dose in spontaneous locomotor (49.4%) and exploratory (59.7%) activities and, mainly, the increase in the time spent by the rat in inactivity (181.7%) were diminished after 7 days of daily treatment (39.4, 40.4, and 31.7%, respectively). This tolerance was accompanied by significant decreases in the density of cannabinoid receptors in the striatum and limbic forebrain, the areas where nerve terminals for nigrostriatal and mesolimbic dopaminergic systems, respectively, which play an important role in those processes, are located.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8115426     DOI: 10.1016/0091-3057(94)90108-2

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  38 in total

Review 1.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

Review 2.  Differential effects of psychoactive drugs in adolescents and adults.

Authors:  Sari Izenwasser
Journal:  Crit Rev Neurobiol       Date:  2005

Review 3.  Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences.

Authors:  J M McPartland; M Glass; R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

4.  Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.

Authors:  Emmanuel Valjent; Jennifer M Mitchell; Marie-Jo Besson; Jocelyne Caboche; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 5.  Activation of G-proteins in brain by endogenous and exogenous cannabinoids.

Authors:  Steven R Childers
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

6.  Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure.

Authors:  Alexander F Hoffman; Murat Oz; Tara Caulder; Carl R Lupica
Journal:  J Neurosci       Date:  2003-06-15       Impact factor: 6.167

7.  Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation.

Authors:  José Antonio López-Moreno; Gustavo González-Cuevas; Fernando Rodríguez de Fonseca; Miguel Navarro
Journal:  J Neurosci       Date:  2004-09-22       Impact factor: 6.167

Review 8.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 9.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

10.  Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia.

Authors:  F Rodríguez De Fonseca; M A Gorriti; A Bilbao; L Escuredo; L M García-Segura; D Piomelli; M Navarro
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.